arrow
B

Bryan T. Hennessy

Beaumont Hospital
H指数:74
被引数:3.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

RETRACTED: Richards et al. Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC). Int. J. Mol. Sci. 2023, 24, 10545

撤回:Richards等人。非受体型蛋白酪氨酸磷酸酶11(PTPN11/Shp2)作为非小细胞肺癌(NSCLC)中的驱动癌基因和新型治疗靶点。国际分子科学杂志,2023年,24卷,10545号

2026-04-290
OAAI
Cutaneous Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies

皮肤免疫相关不良事件及免疫检查点抑制剂对晚期实体器官恶性肿瘤患者的疗效

2025-09-010
OAAI
Implementation of neoadjuvant immunotherapy in stage III melanoma: a modified Delphi consensus study in a European-accredited cancer center in Ireland

在爱尔兰一家获得欧洲认证的癌症中心实施III期黑色素瘤的新辅助免疫疗法:一项改良德尔菲共识研究

2025-09-010
OAAI
Molecular subtyping of endometrial carcinoma cell lines uncovers subtype-specific targetable vulnerabilities

子宫内膜癌细胞的分子分型揭示了分型特异的可靶向易损性

2025-07-240
OAAI
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

MEK1/2抑制剂比尼美替尼与MET抑制剂克唑替尼在RAS突变型晚期结直肠癌 (汞) 患者中的Ia/b期研究

2025-04-100
OAAI
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer
2024-10-040
OAAI
Irish National Analysis of the Clinical and Economic impact of 21-gene Oncotype DX® testing in Early-Stage, 1-3 lymph node positive, Hormone Receptor positive (HR+), HER2-Negative (HER2-), Breast Cancer (BC)
2024-05-020
PRE